(Q34428221)

2 August 2017

1 reference

title

Therapeutic drug monitoring for immunosuppressants (English)

1 reference

2 August 2017

1 reference

Wong SH

1

1 reference

2 August 2017

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

313

1 reference

2 August 2017

issue

1-2

1 reference

2 August 2017

page(s)

241-253

1 reference

FK-506--how much potential?

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Immunosuppression in Liver Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacoeconomics of therapeutic drug monitoring in transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Proceedings of the International Consensus Conference on Immunosuppressive Drugs. Lake Louise, Alberta, Canada, May 5-7, 1995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Recommendations for bioequivalence testing of cyclosporine generics revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Cyclosporine plasma unbound fraction in heart and lung transplantation recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

FK 506 for liver, kidney, and pancreas transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Clinical Pharmacokinetics of Tacrolimus in Heart Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Mycophenolic acid plasma concentrations: influence of comedication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacokinetics of mycophenolic acid in renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Reci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacokinetics and metabolism of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Therapeutic monitoring of mycophenolic acid. A consensus panel report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Failure of traditional trough levels to predict tacrolimus concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

An immunophilin-binding assay for sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Immunophilins: their properties and their potential role in therapeutic drug monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Evaluation of the AxSYM monoclonal cyclosporin assay and comparison with radioimmunoassay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Therapeutic monitoring of tacrolimus (FK506) with the first- and second-generation microparticle enzyme immunoassays: performance and results in four patient populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

An immunoassay for the measurement of sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Stability of sirolimus (rapamycin) in whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Proficiency-testing issues relating to sirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Prediction of tacrolimus blood levels by using the neural network with genetic algorithm in liver transplantation patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Cytokines and their receptors: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

Consensus document: therapeutic monitoring of tacrolimus (FK-506).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900678-7

10.1016/S0009-8981(01)00678-7

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference